In one clinical trial in 2015, overweight or obese adults who took Saxenda for 56 weeks lost an average of 8.4% of their body weight, compared to 2.8% in those who received a placebo
While Ozempic and other GLP-1 medications contain different active molecules and carry distinct brand names, they allegedly cause the same types of severe gastrointestinal complications
GLP-1 market size was evaluated at USD 24.97 billion in 2025 and is projected to reach around USD 77.36 billion by 2035, growing at a CAGR of 11.97% from 2026 to 2035
The medication also slows gastric emptyingthe rate at which food moves from your stomach to your small intestine
Glutathione (GSH) is one of the most powerful natural antioxidants we have at our disposal
Retatrutide para obesidad Ensayo fase 2 (Jastreboff AM, Kaplan LM, Fras JP, et al